Received May 8, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | N/A | 3CB9L | IM / RA |
| TYP | TYPHOID VI POLYSACCHARIDE (TYPHIM VI) | SANOFI PASTEUR | N/A | V2A451M | IM / RL |
| YF | YELLOW FEVER (YF-VAX) | SANOFI PASTEUR | N/A | UJ830AC | SC / LA |
The patient was administered the one-vial preparation of MenVeo instead of the intended two-vial preparation. No adverse events were observed or reported following administration. Upon identification of the variance, the event was documented and the care team was notified.
unknown
unknown
unknown
none